NewAmsterdam Pharma Company NV
NAMS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.25B
Close$
$2.95
89.3% downside
Current Fair Value
89.3% downsideOvervalued by 89.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.25 Billion |
|---|---|
| Enterprise Value | $2.80 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.08 |
| Outstanding Shares | 121,102,500 |
Return
| Return on Equity | -31.98% |
|---|---|
| Return on Assets | -29.04% |
| Return on Invested Capital | -34.88% |
Valuation & Multiples
| P/E Ratio | -15.35 |
|---|---|
| PEG | -68.08 |
| Price to Sales | - |
| Price to Book Ratio | 5.51 |
| Enterprise Value to Revenue | 123.87 |
| Enterprise Value to EBIT | -12.05 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$1.09 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 184.26% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.09%▼ 105.96% |
|---|---|
| Total Invested | $85.93M▼ 97.83% |
| Investors Holding | 31▼ 150.00% |
ESG Score
No data